Inhibition of salvage pathway enzymes by adenine arabinoside 5'-monophosphate (ara-AMP).
The effect of 9-beta-arabinofuranosyladenine 5'-monophosphate (ara-AMP) on the purine salvage pathway has been studied. On a dose-dependent basis ara-AMP inhibits the incorporation of adenine-8-14C into nucleotides in intact erythrocytes. The partially purified enzymes of the purine salvage pathway, the adenine phosphoribosyltransferase and the 5'-phosphoribosyl-1-pyrophosphate (PP-ribose-P) synthetase, but not the hypoxanthine-guanine phosphoribosyltransferase, are inhibited by ara-AMP in a non-competitive manner. The possible adverse drug interactions which might occur by the simultaneous use of ara-AMP and other antimetabolites are discussed.
D000225:Adenine / Q000378:metabolism; D000228:Adenine Phosphoribosyltransferase / Q000037:antagonists & inhibitors*; D001088:Arabinonucleotides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000037:antagonists & inhibitors*; D007700:Kinetics; D010430:Pentosyltransferases / Q000037:antagonists & inhibitors*; D010770:Phosphotransferases / Q000037:antagonists & inhibitors*; D012268:Ribose-Phosphate Pyrophosphokinase / Q000037:antagonists & inhibitors*; D013379:Substrate Specificity; D001084:Vidarabine Phosphate / Q000494:pharmacology*
D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; D010430:Pentosyltransferases; D000228:Adenine Phosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D010770:Phosphotransferases; D012268:Ribose-Phosphate Pyrophosphokinase; D000225:Adenine